{"id":"7c95aaf286cf","type":"article","url":"https://hartvaat.nl/2026/05/06/dronedaron-na-af-ablatie-gelijke-werkzaamheid-minder-bijwerkingen-dan-amiodaron/","title":"Dronedaron na AF-ablatie: gelijke werkzaamheid, minder bijwerkingen dan amiodaron","title_en":"","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag095","source_url":"https://doi.org/10.1093/europace/euag095","authors":["Xuan Zhang","Rong Jiang","Yuxiao Chen","Lian Lou","Shuo Liu","Thida Sok","Jie Han","Dongchen Zhou","Biqi Zhang","Zhihang Li","Wen Shi","Zhen Dai","Xiaosheng Hu","Xiaogang Guo","Jian Yang"],"significance":7,"published":"2026-05-03","source_date":"2026-05-06","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/elektrisch-remodellering-atrium/","https://hartvaat.nl/kennis/atriumfibrilleren/af-en-hartfalen/"],"congress":"","summary_en":"An open-label RCT randomised 280 post-AF-ablation patients to 12 weeks of dronedarone or amiodarone during the blanking period. Atrial tachyarrhythmia recurrence did not differ (23.4% vs 16.9%; p=0.184), but adverse events were far less common with dronedarone (40.9% vs 64.0%; p<0.001), driven mainly by less QTc prolongation (5.8% vs 15.4%) and hypothyroidism (8.8% vs 26.5%). Dronedarone offers comparable rhythm control with a safer profile as bridging therapy after ablation.","created":"2026-07-03T10:32:50Z","updated":"2026-07-03T13:31:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Open-label RCT bij 280 patiënten na atriumfibrillatie-ablatie vergeleek 12 weken dronedaron met amiodaron tijdens de blanking-periode. Recidieven van atriale tachyaritmie verschilden niet (23,4% vs 16,9%; p=0,184), maar bijwerkingen waren significant frequenter met amiodaron (40,9% vs 64,0%; p<0,001), met name QTc-verlenging (5,8% vs 15,4%) en hypothyreoïdie (8,8% vs 26,5%). Dronedaron biedt vergelijkbare ritmecontrole met een gunstiger veiligheidsprofiel als overbruggingstherapie na ablatie.","abstract_original":"AIMS: The high recurrence rate after catheter ablation for atrial fibrillation (AF) remains a challenge. Short-term antiarrhythmic drugs are commonly used during the 3-month blanking period, but the choice between amiodarone and dronedarone is unclear. OBJECTIVES: This trial directly compared the effectiveness and safety of dronedarone vs. amiodarone administered during the blanking period post-ablation in AF. METHODS AND RESULTS: In this open-label, randomized controlled trial, 280 patients undergoing AF ablation were assigned to receive 12 weeks of treatment with either dronedarone or amiodarone, which was discontinued upon completion of this treatment phase as per protocol. The primary endpoint was atrial tachyarrhythmia recurrence (>30 s) after the blanking period. A total of 280 participants were enrolled, of whom 273 were included in the modified intention-to-treat (mITT) analysis. In the mITT analysis, recurrence rates were not significantly different between the dronedarone and amiodarone groups (23.4% vs. 16.9%, P = 0.184). Secondary efficacy endpoints also showed no significant differences. However, the dronedarone group had a significantly lower incidence of side effects (40.9% vs. 64.0%, P < 0.001), primarily due to fewer cases of QTc-interval prolongation (5.8% vs. 15.4%, P = 0.01) and hypothyroidism (8.8% vs. 26.5%, P < 0.001). The intention-to-treat analysis, which included all enrolled participants, yielded results consistent with those of the mITT analysis. CONCLUSION: Therapy with dronedarone during the blanking period after AF ablation was associated with a similar recurrence rate but a superior safety profile compared to amiodarone."}